Search
Login
Register
Menu
Last issue
Home
News
CongressUpdate
Guidelines
Specials
Links
Reimbursement News
All
All
BJH articles
Blog articles
Specials
Search
Forgot Password?
Not a member yet? Register here
Home
/
General
/ Article: JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
“1 year subscription print edition of the Belgian Journal of Hematology (BJH)” has been added to your cart.
View cart
Article: JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
€
3.03
Article: JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis quantity
Add to cart
SKU:
product-article-18806
Category:
General
Description
Description
JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
Related products
Article: Highlights in gynaecological cancers
€
3.03
Add to cart
Article: Calendar of events
€
3.03
Add to cart
Article: Highlights in squamous cell carcinoma of the head and neck
€
3.03
Add to cart
Article: Highlights in melanoma
€
3.03
Add to cart